Key result
Add-on heart failure reversal therapy boosts exercise capacity by ~1.5 METs over standard treatment alone.
Why the study?
The effect of heart failure reversal therapy using herbal procedures as add-on to standard treatment in chronic heart failure patients was evaluated due to limited evidence on its efficacy and safety.
Does heart failure reversal therapy (HFRT) added to standard treatment improve functional capacity (MET and VO2peak) in patients with chronic heart failure?
RCT (n=70)
Open-label
1:1
Does heart failure reversal therapy (HFRT) added to standard treatment improve functional capacity (MET and VO2peak) in patients with chronic heart failure?
Add-on heart failure reversal therapy (HFRT) significantly improved functional capacity and quality of life in patients with chronic heart failure without major safety concerns.
Answers are grounded in this paper and cite their sources.
Supports adding HFRT to standard care to enhance functional capacity in chronic HF; extends RCT evidence for adjunctive therapies.
The present study was designed to evaluate effect of heart failure reversal therapy (HFRT) using herbal procedure (panchakarma) and allied therapies, as add-on to standard CHF treatment (SCT) in chronic heart failure (CHF) patients. This open-label, randomized study conducted in CHF patients (aged: 25–65 years, ejection fraction: 30–65%), had 3-phases: 1-week screening, 6-week treatment (randomized [1:1] to HFRT + SCT or SCT-alone) and follow-up (12-week). Twice weekly HFRT (60–75 min) consisting of snehana (external oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti (enema) was administered. Primary endpoints included evaluation of change in metabolic equivalents of task (MET) and peak oxygen uptake (VO2peak) from baseline, at end of 6-week treatment and follow-up at week-18 (non-parametric rank ANCOVA analysis). Safety and quality of life (QoL) was assessed. Seventy CHF patients (n = 35, each treatment-arm; mean [SD] age: 53.0 [8.6], 80% men) were enrolled in the study. All patients completed treatment phase. Add-on HFRT caused a significant increase in METs (least square mean difference [LSMD], 6-week: 1.536, p = 0.0002; 18-week: −1.254, p = 0.0089) and VO2peak (LSMD, 6-week: −5.52, p = 0.0002; 18-week: −4.517, p = 0.0089) as compared with SCT-alone. Results were suggestive of improved functional capacity in patients with HFRT (QoL; Mean [SD] HFRT + SCT vs. SCT-alone; 6-week: −0.44 [0.34] vs. −0.06 [0.25], p < 0.0001 and 18-week: −0.53 [0.35] vs. −0.29 [0.26], p = 0.0013). Seven treatment-emergent adverse events (mild severity) were reported in HFRT-arm. Findings of this study highlight therapeutic efficacy of add-on HFRT vs. SCT-alone in CHF patients. The non-invasive HFRT showed no safety concerns.
No takes yet. Share an insight, caveat, or question.
Sane et al. (2016) conducted an RCT in chronic heart failure (CHF) (n=70). Heart failure reversal therapy (HFRT) vs. Standard CHF treatment (SCT) alone was evaluated on Change in metabolic equivalents of task (MET) and peak oxygen uptake (VO2peak) from baseline at 6 weeks and 18 weeks (LSMD 1.536, p=0.0002). Add-on heart failure reversal therapy increased metabolic equivalents of task and exercise capacity compared to standard treatment alone at 6 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: